Compare JPMorgan Chase & Co (JPM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs TransMedics Group Inc — how do they compare? JPMorgan Chase & Co trades at $345.38 (market cap $900.78B), while TransMedics Group Inc trades at $75.11 (market cap $2.54B). The key difference: JPMorgan Chase & Co is far larger — about 354.6× TransMedics Group Inc's market cap, and JPMorgan Chase & Co pays a 1.77% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| JPM | TMDX | |
|---|---|---|
Market Cap | $900.78B | $2.54B |
Volume | 10,479,943 | — |
Sector | Financials | Technology |
52-Week High | $346.91 | $150.42 |
52-Week Low | $282.84 | $61.99 |
Dividend Yield | 1.77% | — |
Enterprise Value | — | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $343.94, up 0.83% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to $194.8B projected for 2026. The stock shows robust fundamentals with a P/E of 14.52 and net income margin of 33.4%, though cash flow trends indicate significant investing outflows.
Outlook remains positive with a consensus price target of $372.73, implying ~8.4% upside. Risks include geopolitical tensions affecting oil markets and cybersecurity threats highlighted in recent news. Institutional ownership is stable, supporting a moderate buy rating amid economic uncertainties discussed by CEO Jamie Dimon.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
